Amide Technologies Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Amide Technologies's estimated annual revenue is currently $2M per year.(i)
  • Amide Technologies's estimated revenue per employee is $155,000

Employee Data

  • Amide Technologies has 13 Employees.(i)
  • Amide Technologies grew their employee count by -13% last year.

Amide Technologies's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Operating OfficerReveal Email/Phone
4
Research Associate, Protein SciencesReveal Email/Phone
5
Technical Lead, Senior Scientist, Peptide and Protein Chemistry, Flow technologyReveal Email/Phone
6
Jr. Mechanical EngineerReveal Email/Phone
7
ScientistReveal Email/Phone
8
ScientistReveal Email/Phone
9
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Amide Technologies?

Amide is at the forefront of a new biotech industry—fully synthetic proteins—that boasts the combinatorial flexibility of small molecules, alongside the physiological advantages of biologics. As the experts in this new field, we champion the protein therapeutic 2.0 market. Amide was founded on the seminal inventions of Prof. Brad Pentelute enabling on-demand protein synthesis including non-natural chemical modifications - providing unique protein functionality (affinity, stability, bioavailability, cell membrane penetration) and reduced immunogenicity. Engineered synthetic proteins are coupled with our artificial intelligence (AI) tools to predict performance characteristics of our assets at a scale unattainable with traditional methods for protein synthesis and post-translational modifications. Our pipeline aims to relieve patient suffering and modify the disease course of autoimmune diseases, inflammatory disorders, cancers and COVID19.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$2M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.3M13-7%$8.1M
#2
$2.1M13N/AN/A
#3
$1M13N/AN/A
#4
$0.9M13-7%$9.1M
#5
$1.8M13-28%N/A